Neoadjuvant chemotherapy in locally advanced colon cancer: a systematic review and meta-analysis

R Gosavi, C Chia, M Michael, AG Heriot… - International Journal of …, 2021 - Springer
Background There is increasing evidence to support the use of neoadjuvant chemotherapy
(NAC) in locally advanced colon cancer (LACC). However, its safety, efficacy and side effect …

Metastatic breast cancer: the treatment challenge

SE Jones - Clinical breast cancer, 2008 - Elsevier
As therapeutic options have multiplied, chemotherapy for metastatic breast cancer (MBC)
has become increasingly complex. Furthermore, advances in the treatment of early-stage …

An all-oral combination of metronomic cyclophosphamide plus capecitabine in patients with anthracycline-and taxane-pretreated metastatic breast cancer: a phase II …

Z Wang, J Lu, S Leaw, X Hong, J Wang, Z Shao… - Cancer chemotherapy …, 2012 - Springer
Purpose Oral administration of cyclophosphamide (CTX) and capecitabine may have a
greater potential for treatment of metastatic breast cancer (MBC) due to anti-angiogenesis …

Is there a role for mitomycin C in metastatic colorectal cancer?

A Dimou, KN Syrigos, MW Saif - Expert opinion on investigational …, 2010 - Taylor & Francis
Importance of the field: Fluoropyrimidines with oxaliplatin or irinotecan, bevacizumab,
cetuximab and panitumumab constitute the drugs currently approved by the FDA for the …

Intra-arterial mitomycin C infusion in a large cohort of advanced liver metastatic breast cancer patients: safety, efficacy and factors influencing survival

BM Aarts, EG Klompenhouwer, RC Dresen… - Breast Cancer Research …, 2019 - Springer
Purpose The aim of this study was to determine the safety and efficacy of Mitomycin C
(MMC) infusion in a large cohort of advanced liver metastatic breast cancer patients (LMBC) …

Interventional oncology in breast cancer

F Orsi - Journal of Medical Imaging and Radiation Oncology, 2023 - Wiley Online Library
Breast cancer (BC) is the most common cancer and one of the most important causes of
death in women. Surgery is the standard therapy for breast cancer and in the last decades …

Mitomycin-C and capecitabine (MIXE) as salvage treatment in patients with refractory metastatic colorectal cancer: a retrospective study

MW Saif, K Kaley, M Brennan, MC Garcon… - Anticancer …, 2013 - ar.iiarjournals.org
Aim: To report on the efficacy and safety of mitomycin-C-capecitabine (MIXE) regimen as
salvage chemotherapy regimen for patients with refractory metastatic colorectal cancer …

[HTML][HTML] Phase II study of sequentially administered low-dose mitomycin-C (MMC) and irinotecan (CPT-11) in women with metastatic breast cancer (MBC)

E Mrozek, J Kolesar, D Young, J Allen… - Annals of oncology, 2008 - Elsevier
Background Preclinical studies show that mitomycin-C (MMC) followed by irinotecan (CPT-
11) is synergistic. Therefore, we evaluated the toxicity and efficacy of sequentially …

Mitomycin C in patients with gynecological malignancies

L Kahmann, U Beyer, G Mehlhorn, FC Thiel… - Oncology Research …, 2010 - karger.com
Mitomycin C (MMC) is an effective cytostatic agent used in the treatment of patients with
gynecological malignancies and breast carcinoma. This review presents and discusses the …

Antitumour antibiotics

MM Paz - Anticancer Therapeutics, 2008 - Wiley Online Library
The term 'antitumour antibiotic'is employed to classify substances produced by
microorganisms that exert their anticancer activity by interacting with DNA. In this chapter …